The immunoreactivity of monoclonal antibody (MoAb) B72.3 with ovarian serous tumors of borderline malignancy from 44 women who were pregnant, were on hormone medication containing a progestin, or were known to be in the secretory phase of the menstrual cycle, was compared with that of similar tumors
Distribution of VRA09, an ovarian tumor-associated antigen, distinguishing borderline serous tumors
✍ Scribed by Thibault Voeltzel; Pierre Duvillard; Pascale Ghillani; Jean Bénard; Claude Bohuon; Dominique Bellet; Jean-Michel Bidart
- Book ID
- 102868086
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- French
- Weight
- 794 KB
- Volume
- 59
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
We recently reported the characterization of an antigen designated VRA09, identified by a monoclonal antibody and overexpressed on the surface of vincristine-resistant human ovarian carcinoma cells. In the present study, we analyze the distribution of this antigen in normal and tumor tissues. Its pattern of expression appears to differ from that described for other drug-resistance-and/or tumor-associated antigens. In normal tissues, the antigen has a restricted histological distribution and appears to be localized in mesoderm-derived tissues. In tumor tissues, VRA09 expression was mainly detected in serous ovarian tumors. Indeed, VRA09 is strongly expressed in papillary serous cystadenocarcinomas and their metastases, and more specifically in the basement membranes of serous tumors of borderline malignancy. In contrast, no immunostaining was observed in normal ovarian tissue or benign tumors. The detection of this antigen may help to identify serous ovarian tumors by distinguishing tumors of low malignancy from c ystadenocarcinomas.
📜 SIMILAR VOLUMES